

A Rare Case of Extensive Lichen Planus Eruption during Fixed Dosed Regimen of Anti Tubercular Therapy

Dr. Paladugu Swetha MD^{1*}, Dr. Ananthaxmi MD, DTCD², Dr. Hima Bindhu³, Dr. V.Aruna Sree, DCP, FCD⁴

¹Department of Pulmonary Medicine, ESI hospital, Hyderabad, Telangana, India

²Department of Anaesthesiology, ESI hospital, Hyderabad, Telangana, India

³Department of Dermatology, ESI hospital, Hyderabad, Telangana, India

⁴ESI hospital, Hyderabad, Telangana, India

DOI: [10.36347/sjams.2020.v08i01.055](https://doi.org/10.36347/sjams.2020.v08i01.055)

| Received: 08.01.2020 | Accepted: 21.01.2020 | Published: 30.01.2020

*Corresponding author: Dr. Paladugu Swetha

Abstract

Case Report

Introduction: Lichen Planus is a mucocutaneous disease with idiopathic etiology. Lichenoid drug eruption/Drug induced lichen planus an uncommon adverse effect of several drugs. Lichen planus can be distinguished from Lichenoid drug eruption by clinical and microscopic features. **Case report:** 62 year old male presented with left lung consolidation with effusion. Analysis of pleural fluid was consistent with Koch's etiology. Patient was started on fixed dose regimen of anti-tubercular therapy. Patient developed rash all over the body initially over legs and later on progressed to entire body involving oral mucosa, lips and scalp. On examination purplish to blackish plaques mostly over extremities, and also scalp, buccal mucosa, lips involved. A differential diagnosis of Psoriasisiform lichen planus/Psoriasis/Prurigo nodularis was made and skin biopsy was sent for histopathological examination which showed lichen planus. Dermatologist consultation was taken and patient was started on topical steroids and anti-histamines. Anti tubercular therapy was continued and completed the course for 6 months. Patient is in a verge of relief of symptoms and hyperpigmentation.

Keywords: Extensive, Eruption, Anti Tubercular, Lichen Planus.

Copyright @ 2020: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

INTRODUCTION

Lichen Planus is a chronic inflammatory autoimmune disease occurring in 0.1 to 4% of general population [1]. Lichen Planus can appear at any age, but most cases occur between 30 and 60 years of age [2]. Lichen Planus can be diagnosed clinically in classic cases, although biopsy is often helpful to confirm the diagnosis. The histology shows a characteristic "saw-tooth" pattern of epidermal hyperplasia; hyperparakeratosis with thickening of the granular cell layer and vacuolar alteration of basal layer of epidermis with an intense infiltration at dermal-epidermal junction.

CASE PRESENTATION

We report a case of 62 yrs old male presented with left lung consolidation with effusion. Sputum for acid fast bacilli is negative. Analysis of pleural fluid showed lymphocytic predominance; ADA 48 IU. Analysis of pleural fluid was consistent with tubercular etiology.


Patient was started on anti-tubercular regimen (fixed dose regimen) in February 2019. Three months after initiation of anti-tubercular therapy patient developed an erythematous to violaceous eruption all over the body initially over legs and later on progressed to entire body involving oral mucosa, lips and scalp.

Physical examination revealed purplish to blackish plaques mostly over extremities involving scalp, buccal mucosa and lips.



A differential diagnosis of Psoriasiform lichen planus/Psoriasis/Prurigo nodularis was made. Punch biopsy from skin was sent for histo pathological examination. In hematoxylin and eosin stained sections

from skin biopsy, Epidermis showed hyperkeratosis, Acanthosis. Upper dermis showed band like inflammatory infiltrate, histological features are suggestive of lichen planus.



Dermatologist consultation was taken and patient was started on topical steroids and anti-histamines. Anti-tubercular therapy was continued and completed the course for six months. Patient currently is in a state of resolution of skin lesions.

DISCUSSION

Idiopathic LP usually develops insidiously and can affect any area of the body surface. It is most likely to appear on the wrist, lumbar region, and ankles. Oral

lesions are more pleomorphic and may occur in up to 30-70% of patients. Patients typically complain of pruritus, but this may be completely absent [3]. Drug-induced LP produces lesions that are clinically and histologically indistinguishable from idiopathic LP the two can be differentiated only by the time course of skin or mucous membrane involvement in relation to the drug, and confirmed by rechallenge. Considering the variability in the disorder's natural history, diagnosing drug-induced LP can be difficult, and a definitive diagnosis is generally not possible.

The terms LP-like or lichenoid describe Skin eruptions caused by certain drugs and compounds and can be identical or similar to lichen planus. For most drug eruptions, the latent period between the beginning of administration of a drug and the appearance of the eruption is about 1 or 2 Weeks [4] or up to 1 month [5]. The latent period is dependent on the offending drug but other factors may also play a role in determining its duration, that is, the dosage of the drug, the patient's individual reaction to the drug, and treatment with other drugs. The latent period may be shortened significantly if the patient has been previously exposed to the offending drug [5].

Idiopathic LP has a predilection for the flexor aspect of the forearms and the legs. Moreover, a photo distributed pattern in idiopathic LP is not likely. However, Lichenoid drug eruption usually appears as asymmetric eruption on the trunk and extremities [6]. Involvement of the oral mucosa in Lichenoid drug eruption is less common than in idiopathic LP. It may occur with or without cutaneous involvement

Antitubercular drugs responsible for Lichen Planus eruption are [7, 8].

Ethambutol

P-Amino salicylic acid

Isoniazide

Streptomycin

REFERENCES

1. Ismail SB, Kumar SK, Zain RB. Oral lichen lichenoid reactions: etiopathogenesis, diagnosis and malignant transformation J Oral Sci. 2007;49(2):89-106.
2. Zakrzewska JM, Chan ES, Thornhill MH. A systematic review of placebo-controlled randomized clinical trials of treatments used in oral lichen planus. Br J Dermatol. 2005;153(2):336-341.
3. Dennis E Thompson, Pharm D and Penny A. Skaehill, Pharm. D Drug-Induced Lichen Planus (Pharmacotherapy. 1994; 14(5):516 1-571).
4. Wintroub BU, Stern RS, Arndt KA. Cutaneous reactions to drugs. In: Fitzpatrick TB, Eisen AZ, Wolff K, eds Dermatology in general medicine. 3rd ed, New York: Mc Graw-Hill. 1987:1353-66.
5. De Swarte RD. Drug allergy-problems and strategies. J Allergy Clin Immunol. 1984; 74:209-24.
6. Bork K. Lichenoid eruptions. In: Cutaneous side effects of drugs. Philadelphia: WBSaunders, 1988:170-1.
7. Renkin A. Quatre cas de lichen plan au cours de traitement par streptomycine, PAS et INH. Arch Beig Dermatol Syph. 1958; 14:185-90.
8. Shatin H, Canizares O, Worthington EL. Lichen planuslike eruption due to *para-aminosalicylic acid*. J Invest Dermatol. 1953;23:135.